Biogen Announces $34 Million Q1 Charge, Shares Slip
Biogen (BIIB) shares lost nearly 3% on Monday after the company announced in a regulatory filing that it expects to incur $34 million in pre-tax expenses for the first quarter of this year, according to reporting from Yahoo Finance and The Motley Fool. The charge, which includes in-process research and development costs as well as upfront and milestone payments, will impact the company's net income by roughly $0.19 per share under both GAAP and non-GAAP standards.
Impact on Q1 Earnings
Biogen plans to release its full first-quarter results before market open on Wednesday, April 29. Before this announcement, investors were expecting the company to post a slight year-over-year gain in headline net income, to $2.95 per share. Most of those estimates, however, pre-dated the company's disclosure of this $34 million charge.
While the charge is a setback for the quarter's bottom line, such charges are not uncommon as companies invest in future pipelines or make milestone payments in the biotech sector. Until Biogen provides further detail in its official earnings release, the full extent of the charge's implications for the company's near-term results will remain uncertain.
Stocks365 Take
For active traders, Biogen's pre-announced charge warrants careful monitoring. The market has already reacted to the disclosure, but much will depend on how management addresses the charge and provides broader guidance in the forthcoming quarterly results. We recommend a cautious watch until after the April 29 earnings release, when greater clarity on business momentum and financial impact will be available.
